Physician profile
Hubert James Ford
NPI 1154433613
$94,312.77
in general payments reported to CMS, 2019-2025
11 companies · $24K in 2025
The $24K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,419 · 2021: $2,205 · 2022: $21K · 2023: $21K · 2024: $13K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Travel and Lodging: $8,853 · Food and Beverage: $1,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,474.25 |
| Travel and Lodging | $8,853.16 |
| Food and Beverage | $1,922.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $49,110.65 | 2019-2025 | Remodulin |
| Actelion Pharmaceuticals US, INC. | $23,179.40 | 2022-2024 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $18,949.46 | 2023-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $1,819.00 | 2020-2025 | |
| Chiesi USA, INC. | $446.41 | 2025 | |
| Pfizer INC. | $405.78 | 2025 | |
| Janssen Research & Development, LLC | $263.21 | 2019 | |
| Mannkind Corporation | $112.43 | 2024-2025 | |
| Glaxosmithkline, LLC. | $26.43 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hubert Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.